Free tool
FAERS Monitor: Sodium Phenylacetate and Sodium Benzoate
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 215025 or its brand name (Sodium Phenylacetate and Sodium Benzoate, Sodium Benzoate, Sodium Phenylacetate). Reports on generic versions are filed under their own applications.
Reports
9
Serious
7
78% of reports
Hospitalization
3
Death reported
3
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective5
- hyperglycaemia2
- ammonia decreased1
- anion gap increased1
- blood lactic acid increased1
- brain oedema1
- cerebral infarction1
- drug ineffective for unapproved indication1
- maternal exposure during pregnancy1
- mycoplasma test positive1
- off label use1
- therapy non-responder1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2018 | 3 |
| 2021 | 1 |
| 2022 | 3 |
| 2024 | 1 |
| 2025 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,150 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| ammonia decreased | 1 | 30381.2 | 4723.1 | 7,497 |
| mycoplasma test positive | 1 | 15492.4 | 2424.4 | 3,847 |
| anion gap increased | 1 | 1749.7 | 275.5 | 436 |
| blood lactic acid increased | 1 | 443.7 | 69.9 | 110 |
| brain oedema | 1 | 185.1 | 29.2 | 45 |
| hyperglycaemia | 2 | 128.3 | 37.8 | 142 |
| cerebral infarction | 1 | 95.7 | 15.1 | 23 |
| therapy non-responder | 1 | 52.0 | 8.2 | 12 |
| drug ineffective for unapproved indication | 1 | 42.6 | 6.7 | 10 |
| maternal exposure during pregnancy | 1 | 26.2 | 4.1 | 6 |
| drug ineffectiveSignal | 5 | 8.9 | 4.9 | 29 |
| off label use | 1 | 2.7 | 0.4 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.